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Purpose: We recently demonstrated that molecular therapy using aminoglycosides can overcome the underlying genetic
defect in two zebrafish models of ocular coloboma and showed abnormal cell death to be a key feature associated with
the  optic  fissure  closure  defects.  In  further  studies  to  identify  molecular  therapies  for  this  common  congenital
malformation, we now examine the effects of anti-apoptotic compounds in zebrafish models of ocular coloboma in vivo.
Methods: Two ocular coloboma zebrafish lines (pax2.1/noitu29a and lamb1/gupm189) were exposed to diferuloylmethane
(curcumin) or benzyloxycarbonyl-Val-Ala-Asp(Ome)-fluoromethylketone (zVAD-fmk; a pan-caspase inhibitor) for up
to  8  days  post-fertilization.  The  effects  of  these  compounds  were  assessed  by  morphology,  histology,  terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and western blot analysis.
Results: The size of the coloboma in gup zebrafish mutants treated with diferuloylmethane was greatly reduced. In treated
mutants a reduction in TUNEL staining and a 67% decrease in activated caspase-3 protein were observed. The release of
cytochrome c from the mitochondria into the cytosol was reduced fourfold by in vivo diferuloylmethane treatment,
suggesting that the drug was acting to inhibit the intrinsic apoptotic pathway. Inhibition of caspases directly with zVAD-
fmk also resulted in a similar reduction in coloboma phenotype. Treatment with either diferuloylmethane or zVAD-fmk
resulted in a statistically significant 1.4 fold increase in length of survival of these mutant zebrafish (p<0.001), which
normally succumb to the lethal genetic mutation. In contrast, the coloboma phenotype in noi zebrafish mutants did not
respond to either diferuloylmethane or zVAD-fmk exposure, even though inhibition of apoptotic cell death was observed
by a reduction in TUNEL staining.
Conclusions: The differential sensitivity to anti-apoptotic agents in lamb1-deficient and pax2.1-deficient zebrafish
models, suggests that apoptotic cell death is not a final common pathway in all ocular coloboma genotypes. When
considering anti-cell death therapies for ocular colobomatous defects attention should be paid to the genotype under
investigation.
During early eye development a critical morphogenetic
event is the formation and closure of the optic fissure to allow,
for example, ingression of the hyaloid vasculature to supply
the  developing  retina  [1].  This  process  requires  precisely
coordinated sculpting and folding of epithelial tissue, so that
the edges of the optic fissure can align, converge and fuse. The
most common abnormality of this process, failure of this optic
fissure to close, leads to the congenital malformation known
as ocular coloboma, with an incidence of 0.5–7 per 10,000
births [2]. As an example of failure of developing tissue to
fuse,  ocular  coloboma  can  be  grouped  along  with  other
developmental anomalies such as spina bifida and cleft lip/
palate [3-5]. Potentially affecting the retina, choroid and optic
nerve as well as the iris, it has been reported in up to 11.2%
of  blind  children  worldwide  [6]  making  this  untreatable
developmental abnormality an important area to study.
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The first step in delineating the signaling pathways that
lead to proper folding, apposition and fusion of developing
eye tissue is to identify molecular events causing optic fissure
closure defects [7-13]. Although a large number of genetic
defects have been associated with ocular coloboma [14], the
molecular and cellular mechanisms underlying this are poorly
understood. Data from several sources has however emerged
to suggest that apoptotic cell death pathways are abnormally
activated in cases of coloboma [15,16]. These data suggest
that modulation of apoptotic cell death could be a viable
strategy for inhibiting coloboma formation independent of the
underlying cause [17-19].
We  had  previously  shown  that  the  zebrafish  model
system is particularly suited to drug testing in vivo. In two
ocular coloboma models we showed that translational bypass
of the premature stop codon mutation in each mutant using
aminoglycosides was able to rescue the colobomatous defect
and concomitantly inhibit cell death in the eye [16]. In this
study  we  proposed  to  identify  other  pharmaceutical
approaches to modifying molecular pathways triggered by
coloboma mutations.
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1473Diferuloylmethane (commonly known as curcumin) is a
natural polyphenol component found in the rhizome of the
Curcuma longa plant. Extensive studies have revealed diverse
pharmacological  effects  induced  by  diferuloylmethane
reported both in vitro and in vivo, including anti-inflammatory
[20], antioxidant [21], anti-tumor [22], and neuroprotective
(anti-cell  death)  actions  [23-26].  zVAD-fmk  is  a  broad
spectrum  caspase  inhibitor  that  is  commonly  used  to
investigate cell death signaling in vitro, and several studies
have shown that it has beneficial anti-cell death effect in vivo.
For example, it delays disease onset and extends the survival
in the amyotrophic lateral sclerosis transgenic mouse model
[27],  it  rescues  renal  hypoplasia  in  paired  box  2  (Pax2)-
deficient mice [28] and promotes cochlear hair cell survival
in the Pou4f3 mouse model of deafness [29]. In this study we
tested  the  ability  of  diferuloylmethane  and
benzyloxycarbonyl-Val-Ala-Asp(Ome)-fluoromethylketone
(zVAD-fmk) to attenuate the congenital coloboma phenotype
in zebrafish models of ocular coloboma.
METHODS
Zebrafish  strains  and  maintenance:  Zebrafish  strains
(wildtype  AB  [30],  noitu29a  [31]  and  gupm189  [32])  were
maintained and staged according to morphological criteria
using  established  protocols  [33,34].  The  noi  strain  has  a
nonsense mutation in the pax2.1 gene with a mild coloboma
phenotype, whereas the gup strain has a nonsense mutation in
the  laminin  beta  1  (lamb1)  gene  with  a  severe  coloboma
phenotype.  Research  was  carried  in  accordance  with  the
principles  and  guidelines  of  The  Animals  (Scientific
Procedures) Act 1986, UK, the Canadian Council of Animal
Care and the ARVO statement for the use of animals in vision
research. Embryos were raised at 28.5 °C on a 14 h light/10 h
dark cycle in 100 mm2 Petri dishes containing aquaria water.
To aid image analysis, 0.2 mM phenylthiourea (PTU; Sigma-
Aldrich, Oakville, ON, Canada) was added to the embryos at
10 h post-fertilization (hpf) to inhibit pigment formation.
Anti-apoptosis treatment: All chemicals were obtained from
Sigma-Aldrich (Oakville, ON, Canada). Stock solutions of
zVAD-fmk and zFA-fmk (negative control for zVAD-fmk) in
dimethyl sulfoxide (DMSO) and diferuloylmethane in PBS
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 1.47 mM
KH2PO4, pH of 7.4) were added to aquaria water. Initial dose–
response experiments in zebrafish embryos were performed
to  determine  non-toxic  dosages.  Mutant  embryos  were
dechorionated at 10 hpf and treated with diferuloylmethane,
zVAD-fmk, zFA-fmk or kept in control (drug-free) aquaria
water  until  either  6  or  8  days  post-fertilization  (dpf).  An
equivalent volume of DMSO was added to control cultures
where necessary. For each treatment 30 embryos were used
and  three  independent  experiments  were  performed.
Quantitative  data  are  expressed  as  mean±SEM.  Statistical
analysis of the data by pair-wise comparisons between the
control,  untreated  mutants  and  each  treatment  group  was
performed using the Mann–Whitney test. A p value <0.05 was
considered significant.
Retinal histology and morphological studies: Embryos were
fixed in 4% paraformaldehyde (PFA) overnight at 4 °C before
histological or terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) analysis analysis. After fixation
in  4%  PFA,  embryos  were  washed  3  times  in  PBS  and
dehydrated through a graded ethanol series (50%, 70%, 90%,
and 3 times in 100%). Embryos were transferred into cedar
wood oil and then embedded in paraffin wax. Microtome
sections of 5 µm thickness were cut, mounted on Superfrost
Plus slides (Thermo Scientific, Ottawa, ON, Canada) and
counterstained  with  hematoxylin  and  eosin.  Images  were
captured with an EM-CCD camera (Hamamatsu Photonics
Ltd, Welwyn Garden City, UK) using a widefield Axiovert
microscope Carl Zeiss Inc,  New  York,      NY).    Whole-mount
morphological images were taken with a DFC300 FX camera
(Leica Microsystems Ltd., Milton Keynes, UK) mounted on
a Z16F stereomicroscope (Leica Microsystems Ltd.).
TUNEL  assay:  PTU-treated  embryos  at  6  dpf  from  each
treatment group were fixed in 4% PFA and embedded in wax
as  described  above.  Retinal  sections  were  dewaxed  by
washing twice in Histoclear (National Diagnostics, Hessle,
UK), followed by 2 washes in 100% ethanol and once in 70%
ethanol, before rinsing in deionised H2O. For wholemount
TUNEL assays, embryos were dehydrated through a graded
methanol series (25%, 50%, 75%, and twice in 100%) and
stored in 100% methanol at −20 °C. After rehydration, both
sections  and  wholemount  embryos  were  digested  with
proteinase K (10 μg/ml) for 15 min and 1 h, respectively.
Embryos were refixed with 4% PFA for 20 min at room
temperature (RT), followed by several washed in PBS. The
ApopTag®  Peroxidase  In  Situ  Apoptosis  Detection  Kit
(Millipore,  Bedford,  MA)  was  used  to  detect  levels  of
apoptotic  cell  death,  following  the  manufacturer’s
instructions.
Western  blot  analysis:  Specific  primary  antibodies  were
obtained from commercial sources and used as follows: 1:200
cleaved  caspase-3  rabbit  polyclonal  and  1:2,000
glyceraldehyde  3-phosphate  dehydrogenase  (GAPDH)
mouse  monoclonal  (Abcam,  Cambridge,  MA);  1:500
cytochrome c rabbit polyclonal (Santa Cruz Biotech, Santa
Cruz,  CA);  1:4,000  β-actin  mouse  monoclonal  (Sigma-
Aldrich,  Oakville,  ON,  Canada);  1:1,000  cox  IV  mouse
monoclonal (Acris Antibodies, San Diego, CA).
Briefly, 25 wildtype and mutant embryos at 6 dpf were
snap frozen in liquid nitrogen and homogenized by sonication
in lysis buffer (10 mM Tris pH 7.5, 10 mM NaCl, 1% SDS,
1×  Protease  Inhibitor  Cocktail  (Roche,  Indianapolis,  IN).
Insoluble material was removed by a 10 min centrifugation
(25,000× g). For subcellular fractionation, frozen embryos
were homogenized in hypotonic buffer (50 mM HEPES 7.5,
10 mM NaCl, 1 mM DTT, 1× Protease Inhibitor Cocktail) by
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1474sonication.  Nuclei  and  unbroken  cells  were  pelleted  by
centrifugation at 800× g for 10 min. The supernatant was
collected and centrifuged at 100,000× g for 1 h at 4 °C using
a  Beckman  Optima  Ultracentrifuge  (Beckman  Coulter,
Mississauga,  ON,  Canada)  to  obtain  cytosolic  fractions
(supernatant)  and  mitochondrial  fractions  (pellet).  Protein
concentration was determined by the DC protein assay (Bio-
Rad, Mississauga, ON, Canada).
Equal amounts of protein (40 μg) were separated on a
12% SDS-polyacrylamide gel and transferred to Immobilon-
FL membrane (Millipore, Bedford, MA). The membrane was
incubated in 5% non-fat milk powder in PBS/0.1% Tween-20
(PBST) for 2 h at room temperature and incubated overnight
at 4 °C, simultaneously with two primary antibodies raised in
different hosts. Following 3 washes in PBST, the membrane
was incubated in the dark for 1 h with two Li-COR secondary
antibodies simultaneously (IRDye 680LT goat anti-rabbit;
IRDye 800CW goat anti-mouse; Mandel Scientific, Guelph,
ON, Canada). After the membrane was washed 3 times in
PBST in the dark, protein bands were visualized using a Li-
COR Odyssey detector. The Li-COR software and Image J
were used to quantify band intensity.
RESULTS
Therapeutic  dose  for  diferuloylmethane  and  zVAD-fmk  in
zebrafish: To determine the highest dose of drug that could be
tolerated, we performed survival experiments. The survival
rates of wildtype embryos dosed continuously from 10 hpf
(before  optic  fissure  morphogenesis)  with  increasing
concentrations of diferuloylmethane from 1 μM to 1 mM was
measured at 6 dpf (Figure 1A), and behavioral and gross
morphological  defects  were  noted  in  surviving  larvae.
Embryos  treated  with  5  μM  diferuloylmethane  displayed
normal morphology and behavior with 100% survival rates at
6  dpf,  and  retinal  sections  had  a  normal  histological
appearance at 6 dpf (Figure 1B,C). Doses of >5 μM yielded
toxic  side  effects  including  pericardial  edema,  bent  tails,
spinal  curvature,  shorter  body  length,  and  abnormal
swimming behavior. Doses of ≥12.5 μM were lethal in 100%
of  embryos.  These  results  were  consistent  with  previous
studies  examining  the  effects  of  diferuloylmethane  on
zebrafish development [35]. Hence, a 5 μM concentration was
chosen as the optimum therapeutic dose for in vivo testing in
zebrafish  mutants.  Similar  dose  response  curves  were
performed for zVAD-fmk and zFA-fmk and the optimum
dose of 300 μM for both compounds was determined to have
no toxic side effects (Figure 1D,E).
Effect  of  diferuloylmethane  and  zVAD-fmk  on  coloboma
mutant morphology: Mutant gup embryos were dosed with
5 μM diferuloylmethane or 300 μM zVAD-fmk at 10 hpf and
incubated up to 6 dpf. At 48 hpf, treated gup mutants displayed
a smaller optic fissure closure defect with both drugs (compare
Figure 2A,B with Figure 2C,D), but with similar systemic
features compared to untreated mutants. In contrast, the zFA-
fmk control drug at a concentration of 300 µM had no effect
of the size of the coloboma (Figure 2E). By 6 dpf, the size of
the optic fissure was greatly reduced with both drugs revealing
a  persistent  milder  coloboma  phenotype  (compare  Figure
3A,C with Figure 3E,G) whereas zFA-fmk had no effect on
the coloboma phenotype (Figure 3I). To determine whether
this effect of drug treatment was through a reduction of cell
death, we performed TUNEL-staining (Figure 3B,D,F,H,J).
In  whole-mount  analysis  there  was  no  TUNEL-positive
staining at the position of the optic fissure in treated gup
mutants  compared  to  untreated  mutants,  suggesting  that
diferuloylmethane and zVAD-fmk had caused a reduction in
apoptotic cell death (compare Figure 3D with Figure 3F,H).
To determine whether diferuloylmethane or zVAD-fmk
treatment  would  also  be  effective  in  other  models  of
coloboma, these drugs were tested in the noi mutant model of
coloboma from 10 hpf and incubated up to 6 dpf. When noi
mutant fish were treated with 5 µM diferuloylmethane the
amount of TUNEL-labeled cells present in wholemount fish
was greatly reduced throughout the whole fish and the eye
(compare Figure 4B with Figure 4C). Conversely however,
the  size  of  the  coloboma  appeared  enlarged  rather  than
reduced.  Similarly,  although  300  µM  zVAD-fmk  reduced
TUNEL staining in the fish, it had no discernible effect on the
coloboma defect (Figure 4D).
To further explore this beneficial reduction in coloboma
size seen with diferuloylmethane in gup zebrafish, we used
TUNEL-staining to examine cell death in whole-eye sections
at 6 dpf. Diferuloylmethane treatment again confirmed far
fewer TUNEL-positive cells throughout the eye of mutant
zebrafish compared to untreated zebrafish (Figure 5A). This
experiment however showed that although the size of optic
fissure was reduced, there was no formation of a lens with
diferuloylmethane treatment.
Effect  of  diferuloylmethane  on  caspase  activity  and
mitochondrial  cytochrome  c  release  in  gup  zebrafish:  To
determine if the reduction in TUNEL-positive labeling caused
by diferuloylmethane is a caspase-dependent process, protein
extracts were obtained from 6 dpf embryos and tested for
activated caspase-3 activity by western blot. Zebrafish lysates
from  gup  mutant  fish  displayed  high  levels  of  cleaved
caspase-3 activity (maximally 100%) compared to wildtype
embryos  (2.7%;  Figure  5B).  However,  mutant  embryos
treated with diferuloylmethane had a 67% reduction in the
level  of  cleaved  caspase-3  protein.  We  therefore  tested
whether this reduction in caspase-3 activity was associated
with inhibition of the intrinsic apoptotic pathway, by assessing
whether cytochrome c was released from the mitochondria
into  the  cytosol  [36].  In  wildtype  zebrafish  at  6  dpf,
cytochrome c levels were highest in the mitochondrial fraction
and were only detected at low levels in the corresponding
cytosolic fraction (Figure 6). In untreated mutants at 6 dpf,
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1475Figure 1. Effect of drug treatment on wildtype zebrafish. A: Wildtype embryos were dosed continuously from 10 hpf with diferuloylmethane.
Percentage survival of embryos at 6 dpf was determined for each treatment group (30 embryos/group), n=3, mean±SEM. Error bars smaller
than the symbol are not visible. B-E: Left panels, wholemount eye; center panels, coronal retinal section; right panels, wholemount larvae.
B: Wildtype phenotype untreated at 6 dpf. C: Wildtype phenotype at 6 dpf treated with 5 µM diferuloylmethane from 10 hpf. D: Wildtype
phenotype at 6 dpf following 300 µM zVAD-fmk treatment. E: Wildtype phenotype at 6 dpf following 300 µM zFA-fmk treatment. Scale
bar left panel=200 µm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium, ON,
optic nerve.
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1476Figure 2. Representative morphology of gup mutants at 48 hpf following drug treatment. Left panel, enlarged image of wholemount eye, scale
bar=200 μm. Right panel, whole embryo morphology, scale bar=500 μm. A: Wildtype control, complete closure of optic fissure. B: Untreated
gup mutant, displaying large open optic fissure at ventral aspect of eye. C: gup mutant treated with 5 µM diferuloylmethane, displaying open
optic fissure which is smaller in size compared to untreated mutants. D: gup mutant treated with 300 µM zVAD-fmk, displaying a smaller
open optic fissure than untreated mutants. E: gup mutant treated with 300 µM zFA-fmk, displaying a large open optic fissure as in untreated
mutants. Optic fissure closure defect delineated by black dotted line.
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1477cytochrome  c  was  elevated  sixfold  in  the  cytosol,  with  a
corresponding  reduction  in  the  mitochondrial  fraction.
However,  when  gup  mutants  were  treated  with
diferuloylmethane  from  10  hpf  to  6  dpf,  the  release  of
cytochrome c into the cytosol was greatly reduced to just
twofold over wildtype levels.
Effect of diferuloylmethane and zVAD-fmk on survival: Since
gup mutants showed extensive TUNEL labeling throughout
the  larva,  which  was  reduced  by  the  presence  of
Figure 3. Representative images of drug treatment in gup mutants at 6 dpf. A, C, E, G, I: Enlarged wholemount of the eye, scale=200 µm,
and wholemount larvae, scale=500 µm. B, D, F, H, J: corresponding TUNEL stained wholemount of PTU-treated eye and larvae. A, B:
Wildtype zebrafish showing normal morphology and minimal apoptosis in the eye and wholemount. C, D: Untreated gup mutants displaying
large coloboma in ventral aspect of the eye, TUNEL-positive labeled tissue at the site of the unfused optic fissure and throughout the whole
fish. E, F: gup mutants treated with 5 µM diferuloylmethane (+D) showing small colobomatous defect, minimal TUNEL-positive staining in
the eye, and reduced levels in the whole larvae compared to untreated mutants. G, H: gup mutants treated with 300 µM zVAD-fmk (+V)
showing small colobomatous defect, minimal TUNEL-positive staining in the eye, and reduced levels in the whole larvae compared to untreated
mutants. I, J: gup mutants treated with 300 µM zFA-fmk (+F) showing large colobomatous defect and TUNEL-positive staining at the site
of the unfused fissure.
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1478diferuloylmethane, we speculated whether the mutant larva
would survive past its  usual  life-span of   only  5 days  (the
lamb1 mutation is embryonic lethal). Mutant embryo survival
was  therefore  tested  in  the  presence  of  either:
diferuloylmethane, zVAD-fmk or zFA-fmk. The presence of
diferuloylmethane from 10 dpf increased the embryo life-span
from 5.0±1.0 days to 7.1±1.4 days in treated embryos (Figure
7A), representing a statistically significant (p<0.001)1.4 fold
increase  in  survival.  Similarly,  zVAD-fmk  also  increased
embryo survival from 5.0±1.0 days to 7.0±1.5 days (p<0.001).
No effect on embryo survival was observed with zFA-fmk.
Furthermore, the size of the coloboma was even smaller in
Figure 4. Representative images of the effect of diferuloylmethane on TUNEL-labeling in noi mutant larvae at 6 dpf. A: TUNEL-labeling in
wholemount larvae (left) and wholemount eye (right) of wildtype zebrafish (wt). B: Extensive TUNEL labeling in larvae and eye of untreated
noi mutant zebrafish. C: noi mutant larvae treated with 5 µM diferuloylmethane. D: noi larvae treated with 300 µM zVAD-fmk. Arrow points
to optic fissure closure defect delineated by black dotted line. Scale bar whole eye=200 µm; scale bar larval fish=500 µm.
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1479mutants treated with curcumin or zVAD-fmk at 8 dpf (Figure
7C,D) compared to 6dpf (Figure 3E,G).
DISCUSSION
This study demonstrates that an anti-cell death strategy (using
diferuloylmethane  or  zVAD-fmk)  not  only  substantially
ameliorates  the  ocular  coloboma  phenotype  in  the  gup
(lamb1) zebrafish but also increase embryo survival rate. Our
results also suggest that this reduction in disease severity in
the  gup  model  occurs  through  inhibition  of  the  intrinsic
(mitochondrial) apoptotic pathway via a caspase-3 dependent
mechanism. Persistence of an albeit smaller colobomatous
defect,  and  absence  of  the  lens  with  diferuloylmethane
however suggests that this benefit is partial. Contrastingly, in
a second coloboma model where pax2.1 is deficient (noi line),
apoptotic  cell  death  in  the  eye  was  again  reduced  by
diferuloylmethane and zVAD-fmk, but we could detect no
improvement  in  phenotype,  suggesting  that  caspase-
dependent cell death is not critical in the pathogenesis of
ocular disease in noi zebrafish.
Of the many different mechanisms at play during normal
neurodevelopment,  cell  death,  specifically  apoptotic  cell
death has emerged as an important, late event [37]. During eye
Figure 5. Effect of diferuloylmethane on
cell  death  in  gup  mutant  larvae.  A:
Comparison of TUNEL-positive cells in
coronal  cryosections  of  the  eye  from
mutant gup embryos (left), mutant gup
embryos  treated  with  5  µM
diferuloylmethane  (center)  and
wildtype  embryos  (right)  at  6  dpf.
Histological  sections  counterstained
with  methyl  green.  B:  Representative
western blot of lysates from untreated
mutant  larvae  (gup),  mutant  larvae
treated  with  5  µM  diferuloylmethane
(gup+D)  and  wildtype  larvae  (wt).
Upper  lanes,  correspond  to  cleaved
caspase-3; lower lanes, corresponding
gapdh loading controls.
Figure 6. Representative western blots
showing  cytochrome  c  levels  in  gup
mutants treated with diferuloylmethane.
Cytochrome  c  (cyto  c)  levels  were
determined  in  embryos  treated  for  6
days.  Mitochondrial  and  cytosolic
fractions were normalized with cox IV
or β-actin, respectively. Quantitation of
western  blot  of  cytochrome  c
localization in larvae is shown directly
beneath western blots. Wildtype levels
in  each  fraction  are  set  to  1.0.  Wt,
wildtype; gup, untreated mutant larvae,
gup+D, mutant plus diferuloylmethane.
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1480Figure 7. Effect of caspase inhibition on survival and optic fissure closure. A: Mean survival of gup mutant embryos with no treatment or
with either diferuloylmethane, zVAD-fmk or control inhibitor zFA-fmk. n=30 for each group, mean±SEM (*p<0.001). B: Wildtype (wt)
larval phenotype at 8 dpf. C: Phenotype of gup mutants treated with 5 µM diferuloylmethane. D: Phenotype of gup mutant embryos treated
with 300 µM zVAD-fmk. E: Phenotype of gup mutants treated with 300 μM zFA-fmk. Arrows indicate the position of the coloboma. Size
bar in left panels=200 μm; size bar in right panels=500 μm.
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1481development, we have shown that abnormal apoptotic cell
death  can  be  triggered  during  pathological  states  [16].
Although the in vivo effects of diferuloylmethane are thought
to be diverse [20-22], our TUNEL and western blot studies
suggest that, in the gup zebrafish, diferuloylmethane’s effects
are due to an inhibition of cell death through an attenuation of
the  intrinsic,  mitochondrial  apoptotic  pathway.  This  is  in
keeping with other studies, both in vitro [23,25] and in vivo
[24,26,38]. Our data therefore supports the conclusion that
mitochondrial cytochrome c release, caspase activation and
apoptotic cell death are critical elements of ocular coloboma
pathogenesis in the gup zebrafish and this can be inhibited by
diferuloylmethane  treatment.  Previous  safety  and
bioavailability studies [39-41] suggest that diferuloylmethane
is a viable option for further pre-clinical studies in mammalian
model  systems.  However,  since  ocular  coloboma  is  a
congenital anomaly, in utero safety and bioavailability studies
would  be  needed  before  undertaking  clinical  trials  of
diferuloylmethane or one of its more efficacious analogs.
Contrastingly, our studies in the noi zebrafish suggest that
such a strategy may not be universally applicable in all cases
of ocular coloboma. Although results suggest that apoptotic
cell death is triggered and can be inhibited in the noi zebrafish,
this does not prevent the evolution of a colobomatous eye. A
comparable  situation  is  seen  in  some  retinal  dystrophy
mutants where photoreceptor cell death is a common if not
universal feature [17,19]. Not all mutants however respond to
inhibitors of apoptotic cell death [42-44]. This leads us to
speculate that other cell death mechanisms may be at play in
the noi coloboma model.
Uncharacterized mechanisms other than cell death may
have more critical influences on coloboma pathogenesis in
this noi zebrafish. It is however possible that other cell death
mechanisms in addition to caspase-dependent cell death, are
at play and are more important in the pathogenesis of this
model.  Inhibitors  of  calpain  [45]  and  poly  (ADP-ribose)
polymerase  (PARP)  [46],  key  elements  in  caspase-
independent cell death, have for example been shown to be
effective in some retinal degeneration models. In addition, it
has been shown that in the absence of caspase-dependent cell
death, autophagy cell survival mechanisms can be activated
to stimulate cell death [47,48]. Autophagic cell death has been
shown to be important in normal embryologic development
[49] and play a role in neural tube defects, an epithelial fusion
defect  similar  to  ocular  coloboma  [50].  Inhibitors  of
autophagy have thus been effective in neuronal cell survival
[51] and hepatic fibrosis [52]. Necroptosis, regulated necrosis
without inflammation, has also recently been highlighted as
an  alternative  cell  death  pathway  [53,54].  A  role  for
necroptosis  has  been  established  in  eye  disease  [55]  and
neurodegeneration  [56],  but  a  convincing  role  in
developmental  disease  has  yet  to  be  shown  [57].  The
relevance  of  these  alternate  cell  death  pathways  to  the
pathogenesis  of  ocular  coloboma  awaits  further  study,
however it is likely that cross-talk between many different cell
death pathways [58] determines final cell termination events.
In conclusion, this study highlights caspase-3 dependent
cell death as a critical contributor in some, but not all inherited
forms  of  optic  fissure  closure  defects.  As  more  becomes
known  about  the  different  cell  death  pathways  and  the
associated  genotype-phenotype  correlations,  then  more
specific therapies for different cell death mechanisms can be
formulated.
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